Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

ClinicalTrials.gov ID: NCT00412620

Public ClinicalTrials.gov record NCT00412620. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Study identification

NCT ID
NCT00412620
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Abbott
Industry
Enrollment
156 participants

Conditions and interventions

Conditions

Interventions

  • ABT-925 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2006
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007
Last update posted
Apr 26, 2011

2006 – 2007

United States locations

U.S. sites
11
U.S. states
4
U.S. cities
10
Facility City State ZIP Site status
Site Reference ID/Investigator# 5188 Anaheim California 92805
Site Reference ID/Investigator# 4539 Cerritos California 90703
Site Reference ID/Investigator# 4175 Garden Grove California 92845
Site Reference ID/Investigator# 4553 Pico Rivera California 90660
Site Reference ID/Investigator# 4173 San Diego California 92126
Site Reference ID/Investigator# 4565 Upland California 91786
Site Reference ID/Investigator# 4177 North Miami Florida 33161
Site Reference ID/Investigator# 4168 Atlanta Georgia 30308
Site Reference ID/Investigator# 4567 Austin Texas 78754
Site Reference ID/Investigator# 4176 Austin Texas 78756
Site Reference ID/Investigator# 4371 Bellaire Texas 77401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00412620, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 26, 2011 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00412620 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →